30% revenue growth masks operational deleverage; margin recovery unproven

Persistent reported ₹4,663.9 Cr in revenue (+30.3% YoY) and ₹351.5 Cr in net profit, a decline of 25.4%. Stripping the ₹185.3 Cr in Nagarro acquisition costs (3.1% margin impact), operating PAT sits near ₹494 Cr—roughly 5% YoY growth. That is the real tension: a company growing topline at 30% is seeing underlying profit grow at only 5%. In a software-services business, this signals broken operational leverage.

EBIT margin compressed 130 bps YoY to 15%. Management's bridge is transparent:

The wage hike was a one-time 180 bps shock, disclosed ahead—expected. But the large deal—a 6.5-year, $650M engagement that validates Persistent's Software Reinvention Services—carries a 90 bps margin drag that will stretch across multiple quarters as revenue ramps. Management offered no timeline for when this normalizes, only aspirational language about 16–17% EBIT margin target and 'gradually' reducing drag through FinOps and AI. Gradual is unquantified.

Five shifts from Q1 FY27:

Revenue momentum is real and on track. At USD 487.6M in Q2 (annualized ~$1.95B), Persistent is 97% of the way to its $2B aspiration by end-FY27. TCV hit ₹633.5M (all-time high); top 5 customers are growing 38.9%. The AI software modernization thesis is secular, and the Software Reinvention Services win (6.5-yr, $650M deal) validates both the go-to-market and the proprietary IP (SASVA, iAURA).

Nagarro is scale and capability at global magnitude. Closure expected Q4 CY26 or Q1 CY27 (pending RBI and Austria/Spain FDI approvals) adds 46,000 professionals across 40 countries. Persistent will have served 9 of top 10 tech companies post-deal. Nagarro has ~10% customer overlap; synergies are real and quantifiable (customer expansion, product engineering bench scale, cloud cost optimization). Management will detail the 5–6 month post-close synergy roadmap.

Cash generation is strong. Operating cash flow is ₹4,951.5 Cr; OCF/PAT ratio improved to 96.6% (from 76.2%) despite transaction costs. This cushions refinancing the €1.4B bridge loan (expected 5–6% SOFR-linked rates) and funds growth.

Reported profit growth is absent. Revenue grew 30.3%; profit fell 25.4% reported, and adjusted profit grew only ~5%. This is not working-capital timing or seasonality—it is operational leverage failing to flow through. A 30% software services grower should see 25–35% PAT growth; Persistent showed the opposite.

Margin recovery is unquantified. The 16–17% EBIT margin aspiration is a ceiling with no path. Management offered no waterfall, no quarterly targets, no timeline. The large deal (90 bps drag) persists for quarters; cloud optimization via FinOps is real but unquantified. Until management gives specificity—"Q3 margin X%, Q4 margin Y%"—the 130 bps compression reads as cost control weakness.

Deal size has shrunk. ACV (new bookings) fell from ₹536.8M (Q1) to ₹481M (Q2)—10% decline. Management blamed macro decision slowdown, not productivity. Analysts (Sulabh Govila, Nitin Padmanabhan) pressed hard; management deflected. If slowdown persists into Q3, bookings will also suffer.

Healthcare recovery is unproven timing. HLS grew only 12% YoY (vs. 50%+ in FY25). Management guided recovery from Q3 FY27, citing temporary customer dynamics. But Prateek Maheshwari (HSBC) asked about supply vs. demand; the answer was vague. If healthcare doesn't inflect next quarter, the narrative breaks.

Nagarro execution and refinancing carry risk. ₹25–30M USD in transaction costs over next 3–4 quarters delay margin recovery to late FY27. The €1.4B bridge refinancing at 5–6% is higher-cost than ideal. Synergy realization in post-acquisition integration is execution-dependent, not guaranteed.

Day-1 price action: The stock fell 1.7% on day 1, with 28.8% delivery (shares changing hands), signaling tactical repositioning. The decline was modest but negative—the market priced in weakness.

Valuation context: At ₹5,727.5, the stock sits above all moving averages (SMA20 ₹5,592.6, SMA50 ₹5,571, SMA200 ₹5,334.2), keeping the long-term trend intact. But it is -15.63% off its all-time high of ₹6,788.9. Within the 52-week range (₹4,244.5–₹6,599), the stock occupies the upper third—room to decline if credibility erodes, but also room to run back to ATH if margin recovery accelerates.

Institutional flows: FII ownership fell to 20.79% from 22.12% in Q1 FY27 (−1.33 pp decline). This is a trim, not panic—but signals caution pending Nagarro execution. DII held steady at 30.24% (−0.24 pp), indicating domestic support. Promoters unchanged at 30.29%.

The read: The street is skeptical but not bearish. Revenue thesis is accepted; profit deficit is a warning. FII trim suggests foreign money awaiting margin credibility. Domestic support (steady DII) suggests this is not a fundamental break. The debate resolves when Nagarro closes and synergies become tangible, or when management gives margin guidance.

Quarterly EBIT margin. Revenue is trending well (30% growth, $2B in reach). Customer momentum is improving. The entire debate hinges on whether Persistent restores 16–17% EBIT margin from today's 15%—and on what timeline. If Q3 EBIT margin stays at 15% or drops further, the large deal is not performing and wage normalization didn't help. If Q3 margin expands to 15.3–15.5%, recovery credibility rises. Watch the quarterly progression: 50 bps of improvement per quarter is the baseline to hold the stock.